Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Ophthalmol Ther
.
2023 Oct;12(5):2821-2822.
doi: 10.1007/s40123-023-00788-9.
Authors
Yasuo Yanagi
1
,
Kanji Takahashi
2
,
Tomohiro Iida
3
,
Fumi Gomi
4
,
Junko Morii
5
,
Eriko Kunikane
6
,
Taiji Sakamoto
7
Affiliations
1
Department of Ophthalmology and Microtechnology, Yokohama City University, Kanagawa, Japan. yanagi-tky@umin.ac.jp.
2
Department of Ophthalmology, Kansai Medical University, Osaka, Japan.
3
Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
4
Department of Ophthalmology, Hyogo Medical University, Hyogo, Japan.
5
IQVIA Solutions Japan, K.K., Tokyo, Japan.
6
Senju Pharmaceutical Co., Ltd., Osaka, Japan.
7
Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
PMID:
37566304
PMCID:
PMC10442042
DOI:
10.1007/s40123-023-00788-9
No abstract available
Publication types
Published Erratum